Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.

Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease that belongs to the family of tissue kallikreins (KLKs). Many KLKs are investigated as potential biomarkers for cancer as well as therapeutic drug targets for a number of pathologies. KLK6, in particular, has been implicated in neurodegenerative diseases and cancer, but target validation has been hampered by a lack of selective inhibitors. This work introduces a class of depsipeptidic KLK6 inhibitors, discovered via high-throughput screening, which were found to function as substrate mimics that transiently acylate the catalytic serine of KLK6. Detailed structure-activity relationship studies, aided by in silico modeling, uncovered strict structural requirements for potency, stability, and acyl-enzyme complex half-life. An optimized scaffold, DKFZ-251, demonstrated good selectivity for KLK6 compared to other KLKs, and on-target activity in a cellular assay. Moreover, DKFZ-633, an inhibitor-derived activity-based probe, could be used to pull down active endogenous KLK6.

[1]  A. Lambeir,et al.  Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA). , 2012, Bioorganic & medicinal chemistry.

[2]  D. Cheney,et al.  Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold. , 2013, Bioorganic & medicinal chemistry letters.

[3]  M. Dallman,et al.  Multifunctional Reagents for Quantitative Proteome-Wide Analysis of Protein Modification in Human Cells and Dynamic Profiling of Protein Lipidation During Vertebrate Development** , 2015, Angewandte Chemie.

[4]  V. Magdolen,et al.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs) , 2010, Biochimie.

[5]  Jonathan M. Harris,et al.  Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia , 2010, Biological chemistry.

[6]  E. Benfenati,et al.  Synthesis, biological evaluation, and docking studies of PAR2-AP-derived pseudopeptides as inhibitors of kallikrein 5 and 6 , 2015, Biological chemistry.

[7]  E. Diamandis,et al.  Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid , 2010, Biological chemistry.

[8]  I. Scarisbrick,et al.  Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms , 2018, Biological chemistry.

[9]  A. Scorilas,et al.  Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers , 2012, Clinical chemistry and laboratory medicine.

[10]  W. Neumann,et al.  A new catalytic cross-coupling approach for the synthesis of protected aryl and heteroaryl amidines. , 2002, Organic letters.

[11]  E. Diamandis,et al.  Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. , 2003, Oncology research.

[12]  E. Diamandis,et al.  Kallikrein-related peptidases (KLKs) and the hallmarks of cancer , 2016, Critical reviews in clinical laboratory sciences.

[13]  J. Clements,et al.  The kallikrein-related peptidase family: Dysregulation and functions during cancer progression. , 2016, Biochimie.

[14]  M. Bogyo,et al.  New approaches for dissecting protease functions to improve probe development and drug discovery , 2012, Nature Structural &Molecular Biology.

[15]  Matthew Bogyo,et al.  Application of activity-based probes to the study of enzymes involved in cancer progression. , 2008, Current opinion in genetics & development.

[16]  B. Cravatt,et al.  Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. , 2005, Chemistry & biology.

[17]  V. Lisowski,et al.  Inhibitors of kallikrein‐related peptidases: An overview , 2018, Medicinal research reviews.

[18]  N. Ostermann,et al.  Small-molecule factor D inhibitors targeting the alternative complement pathway. , 2016, Nature chemical biology.

[19]  Moses Rodriguez,et al.  Kallikrein 6 Regulates Early CNS Demyelination in a Viral Model of Multiple Sclerosis , 2012, Brain pathology.

[20]  J. Clements,et al.  Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum. , 2017, The Journal of investigative dermatology.

[21]  N. Grabe,et al.  Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients , 2015, Molecular Cancer.

[22]  C. Craik,et al.  Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer , 2010, Biological chemistry.

[23]  E. Diamandis,et al.  The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6) , 2012, Clinical chemistry and laboratory medicine.

[24]  M. Blaber,et al.  Expression and function of the Kallikrein-related peptidase 6 in the human melanoma microenvironment , 2011, The Journal of investigative dermatology.

[25]  I. Morize,et al.  Virtual Screening and X-ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group. , 2012, ACS medicinal chemistry letters.

[26]  E. Diamandis,et al.  Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease , 2018, Alzheimer's Research & Therapy.

[27]  I. Morize,et al.  Dimerization of β-tryptase inhibitors, does it work for both basic and neutral P1 groups? , 2012, Bioorganic & medicinal chemistry letters.

[28]  E. Diamandis,et al.  Distribution of 15 human kallikreins in tissues and biological fluids. , 2007, Clinical chemistry.

[29]  L. Mueller,et al.  Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening. , 2015, Journal of medicinal chemistry.

[30]  V. Magdolen,et al.  Insights into the activity control of the kallikrein-related peptidase 6: small-molecule modulators and allosterism , 2018, Biological chemistry.

[31]  G. Sotiropoulou,et al.  KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species , 2016, Oncotarget.

[32]  M. Poręba,et al.  Emerging challenges in the design of selective substrates, inhibitors and activity‐based probes for indistinguishable proteases , 2017, The FEBS journal.

[33]  Xin Chen,et al.  Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening. , 2012, Bioorganic & medicinal chemistry letters.

[34]  Brandon L. Parkhurst,et al.  Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors. , 2016, ACS medicinal chemistry letters.

[35]  G. Poda,et al.  Unleashing the therapeutic potential of human kallikrein-related serine proteases , 2015, Nature Reviews Drug Discovery.

[36]  V. Kinsler,et al.  Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold – A Potential Therapeutic Intervention for Skin Diseases , 2016, PloS one.

[37]  Young Yang,et al.  Kallikrein-related peptidase 6 induces chemotherapeutic resistance by attenuating auranofin-induced cell death through activation of autophagy in gastric cancer , 2016, Oncotarget.

[38]  J. Clements,et al.  Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. , 2010, Endocrine reviews.

[39]  Matthew Bogyo,et al.  Activity based probes for proteases: applications to biomarker discovery, molecular imaging and drug screening. , 2007, Current pharmaceutical design.

[40]  James R. Miller,et al.  Zyme, a Novel and Potentially Amyloidogenic Enzyme cDNA Isolated from Alzheimer’s Disease Brain* , 1997, The Journal of Biological Chemistry.

[41]  G. Sotiropoulou,et al.  Targeting the kallikrein-related peptidases for drug development. , 2012, Trends in pharmacological sciences.

[42]  G. Sotiropoulou,et al.  Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation , 2010, Biological chemistry.

[43]  J. Uhm,et al.  Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma. , 2013, Neuro-oncology.

[44]  B. Katz,et al.  Discovery of novel heterocyclic factor VIIa inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[45]  G. Caliendo,et al.  Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development. , 2012, Journal of medicinal chemistry.

[46]  Moses Rodriguez,et al.  Targeting kallikrein 6‐proteolysis attenuates CNS inflammatory disease , 2004, The FASEB Journal.

[47]  Robert A Copeland,et al.  Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. , 2005, Methods of biochemical analysis.

[48]  M. Blaber,et al.  The autolytic regulation of human kallikrein-related peptidase 6. , 2007, Biochemistry.

[49]  M. Okada,et al.  Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand. , 2006, Bioorganic & medicinal chemistry.

[50]  S. Sieber,et al.  Phenyl Esters Are Potent Inhibitors of Caseinolytic Protease P and Reveal a Stereogenic Switch for Deoligomerization. , 2015, Journal of the American Chemical Society.

[51]  E. Diamandis,et al.  Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers , 2014, Critical reviews in clinical laboratory sciences.